Meredith Libeg

FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy

Dickran Kazandjian, Daniel L. Suzman, Gideon M. Blumenthal et al. · The Oncologist · 2016 · 478 citations · Full text

Medicine, Oncology, Pharmacology +12

U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab

Maitreyee Hazarika, Meredith K. Chuk, Marc R. Theoret et al. · Clinical Cancer Research · 2017 · 182 citations

Medicine, Pharmacology, Pharmacotherapy +17

FDA Approval of Nivolumab for the First-Line Treatment of Patients with BRAFV600 Wild-Type Unresectable or Metastatic Melanoma

Julia A. Beaver, Marc R. Theoret, Sirisha L. Mushti et al. · Clinical Cancer Research · 2017 · 60 citations

Medicine, Oncology, Pharmacology +10

Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy

Dickran Kazandjian, Sean Khozin, Gideon M. Blumenthal et al. · JAMA Oncology · 2015 · 52 citations · Full text

Medicine, Oncology, Pharmacology +17